|
1
|
Bahn RS: Graves' ophthalmopathy. N Engl J
Med. 362:726–738. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Barrio-Barrio J, Sabater AL, Bonet-Farriol
E, Velázquez-Villoria Á and Galofré JC: Graves' ophthalmopathy:
VISA versus EUGOGO classification, assessment, and management. J
Ophthalmol. 2015(249125)2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bartalena L, Baldeschi L, Boboridis K,
Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M and Wiersinga
WM: European Group on Graves' Orbitopathy (EUGOGO). The 2016
European Thyroid Association/European Group on Graves' Orbitopathy
Guidelines for the management of Graves' Orbitopathy. Eur Thyroid
J. 5:9–26. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Dibas A and Yorio T: Glucocorticoid
therapy and ocular hypertension. Eur J Pharmacol. 787:57–71.
2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Gao G, Dai J, Qian Y and Ma F:
Meta-analysis of methylprednisolone pulse therapy for Graves'
ophthalmopathy. Clin Exp Ophthalmol. 42:769–777. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ebner R, Devoto MH, Weil D, Bordaberry M,
Mir C, Martinez H, Bonelli L and Niepomniszcze H: Treatment of
thyroid associated ophthalmopathy with periocular injections of
triameinolone. Br J Ophthalmol. 88:1380–1386. 2004.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Alkawas AA, Hussein AM and Shahien EA:
Orbital steroid injection versus oral steroid therapy in management
of thyroid-related ophthalmopathy. Clin Exp Ophthalmol. 38:692–697.
2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Frueh BR: Why the NO SPECS classification
of Graves' eye disease should be abandoned, with suggestions for
the characterization of this disease. Thyroid. 2:85–88.
1992.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Mourits MP, Koornneef L, Wiersinga WM,
Prummel MF, Berghout A and van der Gaag R: Clinical criteria for
the assessment of disease activity in Graves' ophthalmopathy: A
novel approach. Br J Ophthalmol. 73:639–644. 1989.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Mourits MP, Prummel MF, Wiersinga WM and
Koornneef L: Clinical activity score as a guide in the management
of patient with Graves' ophthalmopathy. Clin Endocrinol. 47:9–14.
1997.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wiersinga WM, Prummel MF, Mourits MP,
Koornneef L and Buller HR: Classification of the eye changes of
Graves' disease. Thyroid. 1:357–360. 1991.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bartalena L, Pinchera A and Marcocci C:
Management of Graves' Ophthalmopathy: Reality and perspectives.
Endocr Rev. 21:168–199. 2000.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Watts P, Nayak H, Lim MK, Ashcroft A,
Madfai HA and Palmer H: Validity and ease of use of a computerized
Hess chart. J AAPOS. 15:451–454. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Nakamura T, Wakakura M and Ishikawa S:
Exophthalmometric values in contemporary Japanese population. Jpn J
Clin Ophthalmol. 46:1031–1035. 1992.
|
|
15
|
McCullagh P: Regression models for ordinal
data. J R Stat Soc. 42:109–142. 1980.
|
|
16
|
Ananth CV and Kleinbaum DG: Regression
model for ordinal responses: A review of methods and applications.
Int J Epidemiol. 26:1323–1332. 1997.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bender R and Grouven U: Using binary
logistic regression models for ordinal data with non-proportional
odds. J Clin Epidemiol. 51:809–816. 1998.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Adeleke KA and Adepoju AA: Ordinal
logistic regression model: An application to pregnancy outcomes. J
Math Stat. 6:279–285. 2010.
|
|
19
|
Xu D, Liu Y, Xu H and Li H: Repeated
triamcinolone acetonide injection in the treatment of upper lid
retraction in patients with thyroid-associated ophthalmopathy. Can
J Ophthalmol. 47:34–41. 2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zoorob RJ and Cender D: A different look
at corticosteroids. Am Fam Physician. 58:443–450. 1998.PubMed/NCBI
|
|
21
|
Bagheri A, Abbaszadeh M and Yazdani S:
Intraorbital steroid injection for active thyroid ophthalmopathy. J
Ophthalmic Vis Res. 15:69–77. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Vestergaard P: Smoking and thyroid
disorders-A meta-analysis. Eur J Endocrinol. 146:153–161.
2002.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hegediüs L, Brix TH and Vestergaard P:
Relationship between cigarette smoking and Graves' ophthalmopathy.
J Endocrinol Invest. 27:265–271. 2004.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hiromatsu Y, Eguchi H, Tani J, Masataka K
and Yasuo T: Graves' Ophthalmopathy: Epidemiology and natural
history. Intern Med. 53:353–360. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wall JR and Lahooti H: Pathogenesis of
thyroid eye disease-does autoimmunity against the TSH receptor
explain all cases. Endokrynol Pol. 61:222–227. 2010.PubMed/NCBI
|
|
26
|
Stan MN and Bahn RS: Risk factors for
development or deterioration of graves' ophthalmopathy. Thyroid.
20:777–783. 2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Träisk F, Tallstedt L, Abraham-Nordling M,
Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz
M, Nyström E, et al: Thyroid-associated ophthalmopathy after
treatment for Graves' hyperthyroidism with antithyroid drugs or
iodine-131. J Clin Endocrinol Metab. 94:3700–3707. 2009.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Bartalena L, Marcocci C, Bogazzi F,
Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M,
Bartolomei MP, Lepri A, et al: Relation between therapy for
hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J
Med. 338:73–78. 1998.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wang R, Tan J, Zhang G, Zheng W and Li C:
Risk factors of hepatic dysfunction in patients with Graves'
hyperthyroidism and the efficacy of 131 iodine treatment. Medicine.
96(e6035)2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Louvet C, De Bellis A, Pereira B, Bournaud
C, Kelly A, Maqdasy S, Roche B, Desbiez F, Borson-Chazot F,
Tauveron I and Batisse-Lignier M: Time course of Graves'
orbitopathy after total thyroidectomy and radioiodine therapy for
thyroid cancer. Medicine (Baltimore). 95(e5474)2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Jones R III and Rhee DJ:
Corticosteroid-induced ocular hypertension and glaucoma: A brief
review and update of the literature. Curr Opin Ophthalmol.
17:163–167. 2006.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Skuta GL and Morgan RK: Corticosteroid
induced glaucoma. In: The glaucoma. Ritch R, Shields MB and Krupin
T (eds). 2nd edition. Mosby, St. Louis, MO, pp17721188, 1996.
|
|
33
|
Razeghinejad MR and Katz LJ:
Steroid-induced iatrogenic glaucoma. Ophthalmic Res. 47:66–80.
2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Mahajan VK, Sharma NL, Sharma RC and Garg
G: Twelve-year clinico-therapeutic experience in pemphigus: A
retrospective study of 54 cases. Int J Dermatol. 44:821–827.
2005.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Abramavicius S, Velickiene D and
Kadusevicius E: Methimazole-induced liver injury overshadowed by
methylprednisolone pulse therapy. Medicine.
96(e8159)2017.PubMed/NCBI View Article : Google Scholar
|
